Polio Vaccine Allergy: Triple-Antibiotic IPV and the Neomycin Rule

Inactivated polio vaccine (IPV) made by Sanofi Pasteur as IPOL contains trace amounts of three antibiotics used to prevent bacterial contamination during cell-culture manufacturing: neomycin, streptomycin, and polymyxin B. This triple-antibiotic formulation is unique among routine US vaccines. The amounts present in the final product are extremely small — at the parts-per-million level — but sufficient to trigger reactions in patients with confirmed IgE-mediated allergy to any of the three. Combination products that incorporate IPV (Pediarix, Kinrix, Quadracel, Vaxelis) carry the same trace antibiotic profile and the same contraindication considerations.

It depends on the kind of neomycin allergy. Type IV delayed contact dermatitis to topical neomycin — the pattern identified by patch testing and seen in 8 to 13 percent of dermatology patch-test populations — is explicitly NOT a contraindication to IPV per CDC and ACIP guidance. Only a clear history of generalized urticaria, angioedema, bronchospasm, or anaphylaxis after neomycin exposure rises to a true contraindication. Most patients labeled with "neomycin allergy and IPV" are cleared for routine vaccination after allergist patch-test evaluation rather than excluded from the vaccine.

Inactivated polio vaccine (IPV, marketed as IPOL in the US) contains killed poliovirus and is administered by intramuscular injection. Oral polio vaccine (OPV), no longer used in the US since 2000, contained live attenuated virus given as oral drops. OPV provided excellent mucosal immunity and was easier to administer in mass campaigns but carried a rare risk of vaccine-associated paralytic polio (VAPP) at approximately 1 per 2.4 million doses and could revert to virulence in under-vaccinated populations. Switching to IPV-only in the US eliminated VAPP entirely at the cost of slightly weaker mucosal immunity.

Routine polio boosters are not recommended for adults in the US because wild-type polio has been eliminated in the country and most adults were vaccinated in childhood. However, adults traveling to regions with circulating wild-type poliovirus or vaccine-derived poliovirus may receive a one-time IPV booster per CDC travel medicine guidance. Healthcare workers, laboratory workers handling poliovirus, and certain occupationally exposed groups may also receive boosters. Adults who were never vaccinated in childhood can complete a three-dose IPV primary series at any age following the standard ACIP schedule and intervals.

Vaccine-associated paralytic polio was a rare complication of the older oral polio vaccine (OPV) in which the live attenuated virus regained neurovirulence and caused clinical paralysis, most often in the vaccinated person or a close contact. Incidence was roughly 1 per 2.4 million OPV doses, concentrated in first doses in immunocompromised hosts. VAPP is not an allergy — it is a genuine vaccine-derived infection — but it is historically conflated with vaccine reactions and occasionally appears in family histories as "reaction to polio vaccine." VAPP does not occur with inactivated IPV and is not a relevant US risk today.

No. Inactivated polio vaccine contains no egg protein and no gelatin. Poliovirus for IPOL is grown in Vero cell culture rather than in eggs or animal tissues that would introduce those allergens. This distinguishes IPV from vaccines such as yellow fever (egg-based and egg-contraindicated) and MMR/Varivax (which contain hydrolyzed gelatin). The main IPV excipient concerns are the three trace antibiotics, residual formaldehyde from the inactivation step, 2-phenoxyethanol as a preservative, and calf bovine serum albumin from the growth medium — none of which include egg or gelatin proteins.

If you have confirmed IgE-mediated anaphylaxis to one of the IPV trace antibiotics, you should avoid all IPV-containing products — including Pediarix (DTaP-HepB-IPV), Kinrix (DTaP-IPV), Quadracel (DTaP-IPV), and Vaxelis (DTaP-IPV-Hib-HepB) — and instead receive separate DTaP, HepB, and Hib injections at each pediatric visit. If you were labeled with IPV allergy based on Type IV contact dermatitis to neomycin, an allergist can typically clear you to receive combination vaccines routinely because Type IV sensitization does not predict IgE anaphylaxis to trace quantities.

During the cell-culture manufacturing of IPV, the three antibiotics — neomycin, streptomycin, and polymyxin B — work together to prevent bacterial contamination of the growth medium across a broad spectrum of potential contaminants. Neomycin and streptomycin are aminoglycosides targeting Gram-negative and some Gram-positive bacteria, while polymyxin B targets Gram-negative bacteria through a different mechanism. The combination provides robust contamination control during poliovirus production. Trace residual amounts remain in the final product after purification, which is what drives the clinical antibiotic allergy considerations at the point of administration.